Blood Cell Technologies
Early-stage R&D biopharmaceutical company focused on identification, validation and preclinical development of novel cellular drug targets, small-molecule inhibitors, and biomarkers with emphasis on hematology, metabolism, antioxidant biology and oncology. Active in target discovery, medicinal chemistry, structure-informed design, biomarker development and preclinical validation.
Industries
N/A
Products
BLVRB inhibitor development program
Preclinical development program for small-molecule inhibitors of biliverdin IXβ reductase (BLVRB) intended to enhance megakaryocyte and platelet production.
BLVRB inhibitor development program
Preclinical development program for small-molecule inhibitors of biliverdin IXβ reductase (BLVRB) intended to enhance megakaryocyte and platelet production.
Services
Drug discovery and lead optimization
Discovery, design and optimization of small-molecule inhibitors targeting validated hematology-related enzymes; includes computational design, synthesis and preclinical testing.
Drug discovery and lead optimization
Discovery, design and optimization of small-molecule inhibitors targeting validated hematology-related enzymes; includes computational design, synthesis and preclinical testing.
Expertise Areas
- Target identification and validation
- Small-molecule drug discovery and medicinal chemistry
- Structure-based drug design
- Biomarker discovery and assay development
Key Technologies
- Computational molecular modeling
- X-ray crystallography / structure-guided design
- De novo organic synthesis
- Small-molecule biochemical and cellular screening